Logo Mark
Publications

EHA 2020

All Publications

Treatment with Imetelstat Provides Durable Transfusion Independence (TI) in Heavily Transfused Non-Del(5Q) Lower Risk MDS (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs)

Clinical Imetelstat: MDSImetelstat
EHA 2020

Platzbecker, et al.

Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits in Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Clinical Imetelstat: MFImetelstat
EHA 2020

Mascarenhas, et al.

Imetelstat Treatment Results in Clinical Benefits, Including Improved Overall Survival, in Patients with Higher-Risk Triple-Negative Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitors (JAKi)

Clinical Imetelstat: MFImetelstat
EHA 2020

Kiladjian, et al.

Telomerase Activity, Telomere Length and hTERT Expression Correlate with Clinical Outcomes in Higher-Risk Myelofibrosis (MF) Relapsed/Refractory (R/R) to Janus Kinase Inhibitor Treated with Imetelstat

Clinical Imetelstat: MFImetelstat
EHA 2020

Mascarenhas, et al.

[facetwp facet="publication_load_more"]